Chardan Capital Estimates Metagenomi FY2025 Earnings

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Metagenomi in a report issued on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings per share of ($1.47) for the year. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi's FY2026 earnings at ($0.76) EPS.

Metagenomi (NASDAQ:MGX - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The firm had revenue of $9.61 million during the quarter, compared to analysts' expectations of $13.18 million. Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. During the same quarter in the prior year, the company posted ($20.05) earnings per share.

Several other equities research analysts have also commented on MGX. HC Wainwright boosted their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, December 10th. Wells Fargo & Company lowered their target price on Metagenomi from $25.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday, March 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $14.40.

Metagenomi Stock Down 4.4 %

NASDAQ:MGX traded down $0.07 during mid-day trading on Thursday, reaching $1.42. The company's stock had a trading volume of 155,076 shares, compared to its average volume of 922,759. Metagenomi has a 1 year low of $1.41 and a 1 year high of $10.94. The stock has a fifty day moving average of $2.25 and a 200-day moving average of $2.43. The firm has a market capitalization of $52.90 million and a PE ratio of -0.54.

Institutional Trading of Metagenomi

Hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank purchased a new stake in Metagenomi in the fourth quarter valued at about $1,300,000. Peapod Lane Capital LLC acquired a new stake in Metagenomi in the 4th quarter worth approximately $1,268,000. Geode Capital Management LLC grew its position in Metagenomi by 73.8% during the 4th quarter. Geode Capital Management LLC now owns 587,421 shares of the company's stock worth $2,121,000 after purchasing an additional 249,390 shares during the last quarter. Northern Trust Corp increased its stake in Metagenomi by 185.6% during the 4th quarter. Northern Trust Corp now owns 223,934 shares of the company's stock valued at $808,000 after purchasing an additional 145,536 shares in the last quarter. Finally, Good Life Advisors LLC purchased a new position in shares of Metagenomi in the fourth quarter worth $451,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.